Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zilebesiran

Oligonucleotide (siRNA) · Gene silencing: angiotensinogen (AGT) · developed by Alnylam Pharmaceuticals

Phase 3 Most advanced trial

ALNY Developer

2 Registered trials

What is Zilebesiran?

Zilebesiran (ALN-AGT01) is a small interfering RNA given by subcutaneous injection. It is studied in high cardiovascular risk and hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ALN-AGT01
Drug type: Oligonucleotide (siRNA)
Targets: angiotensinogen (AGT)
Mechanism: Gene silencing: angiotensinogen (AGT)
Therapy area: Cardiovascular
Developer: Alnylam Pharmaceuticals (ALNY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07181109	Phase 3	High Risk Cardiovascular Disease	Recruiting	ALNY
NCT04936035	Phase 2	Hypertension	Completed	ALNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

High Cardiovascular RiskHigh Risk Cardiovascular DiseaseHypertension

Other drugs acting on AGT

ALN-AGT01 RVR Phase 2 IONIS-AGT-LRx Phase 2

More from Alnylam Pharmaceuticals

Givosiran FDA approved Lumasiran FDA approved Patisiran FDA approved Vutrisiran FDA approved ALN-2232 Phase 1/2 ALN-4285 Phase 1 ALN-4324 Phase 2 ALN-4915 Phase 1 ALN-5288 Phase 1 ALN-6222 Phase 1 ALN-6400 Phase 1/2 ALN-AGT01 RVR Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALNY page.

Follow ALNY, the company behind Zilebesiran

See ALNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALNY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z